Solidus Investment

Dr.Diary is a company that provides a comprehensive diabetes management application aimed at helping users monitor and manage their condition effectively. Founded in 2017 and based in Seoul, South Korea, the application allows users to track their blood glucose levels, exercise routines, and food intake, while offering insights on how these factors influence their health. In addition to these features, the platform includes medicine intake reminders, monthly health reports, and daily tips on diabetes management. It also facilitates communication with friends and provides personal consultation services with healthcare professionals, enhancing the overall user experience in managing diabetes.

Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on creating anti-cancer drugs through its innovative proteolysis targeting chimera platform technology. This approach employs inhibitor technology to degrade specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with targeted diseases, Ubix Therapeutics seeks to provide effective and life-saving treatments for patients, thereby supporting medical professionals in their efforts to combat cancer.

Neurophet, Inc. is a neuroscience company based in Seoul, South Korea, founded in 2016. It specializes in developing innovative software solutions for brain stimulation and treatment of neurological disorders. The company's flagship product, Neurophet tES Lab, is a simulation software that calculates and visualizes the effects of brain stimulation by utilizing individual brain structures and specific stimulation conditions. Neurophet employs its proprietary Segengine technology, which can automatically segment brain magnetic resonance images into 107 distinct regions within a minute. This technology aids in predicting and investigating stimulation effects for conditions such as Alzheimer's disease, providing clinicians with a three-dimensional brain model and stimulation parameter guidance. By leveraging deep learning and numerical optimization techniques, Neurophet enables healthcare professionals to focus interventions on targeted regions of the brain, enhancing treatment efficacy for patients with brain diseases.

Himedi, Inc. is a digital health platform based in Seoul, South Korea, founded in 2011. The company connects international patients with medical service providers in South Korea, facilitating access to healthcare services. Himedi offers a hospital reservation service and provides consultations with doctors, while also recommending clinics suited to the patients' needs. Additionally, service managers accompany clients throughout their medical journeys, ensuring a seamless experience. This approach aims to enhance the quality of life for medical tourists by offering tailored healthcare solutions and support during their stay.

Orum Therapeutics is a private biotechnology company based in Daejeon, South Korea, founded in 2016. The company specializes in the research and development of therapeutic antibodies through its innovative cell-penetrating antibody platform, Oromab™. This platform is designed to target cytosolic proteins, addressing unmet medical needs in cancer and rare genetic diseases. Orum's unique approach allows for the intracellular delivery of active antibody therapeutics or payloads, enabling the inhibition of drug targets that have been previously considered undruggable by conventional small molecules or antibody therapies. Orum's technology is adaptable to various cell types and intracellular proteins without requiring chemical modifications, aiming to develop effective treatments with improved specificity and reduced toxicity.

Orum Therapeutics is a private biotechnology company based in Daejeon, South Korea, founded in 2016. The company specializes in the research and development of therapeutic antibodies through its innovative cell-penetrating antibody platform, Oromab™. This platform is designed to target cytosolic proteins, addressing unmet medical needs in cancer and rare genetic diseases. Orum's unique approach allows for the intracellular delivery of active antibody therapeutics or payloads, enabling the inhibition of drug targets that have been previously considered undruggable by conventional small molecules or antibody therapies. Orum's technology is adaptable to various cell types and intracellular proteins without requiring chemical modifications, aiming to develop effective treatments with improved specificity and reduced toxicity.

Alteogen Inc. is a biopharmaceutical company founded in 2008 and based in Daejeon, South Korea. The company specializes in developing next-generation biobetters, antibody-drug conjugates, and antibody biosimilars. Its portfolio includes several innovative products, such as ALT-P1, a long-acting human growth hormone currently in Phase IIa clinical trials, and ALT-Q2, a long-acting coagulation factor VII for hemophilia treatment based on NexP technology. Additionally, Alteogen is developing ALT-P7, a targeted treatment for breast and gastric cancer in Phase I trials, and ALT-Q5, an antibody-drug conjugate for ovarian cancer utilizing NexMab technology. The company has established strategic alliances with Kissei Pharmaceutical for Aflibercept, which has completed pre-clinical trials, and with Cristalia for Trastuzumab, currently in Phase II trials for breast cancer. Through these efforts, Alteogen aims to enhance the efficacy and accessibility of biopharmaceuticals.

Novarex Co., Ltd. is a South Korean company specializing in the development and production of health functional foods and raw materials, both domestically and internationally. Founded in 2008 and headquartered in Cheongju, the company offers a diverse range of dietary supplements, including lactic acid bacteria, probiotics, omega-3 products, and vitamins. Novarex also provides health products tailored for specific needs, such as eye health, dietary support, and maternal and children's nutrition. The product formats include tablets, hard capsules, powders, gumi jellies, and stick jellies. Originally known as Health Science Co., Ltd., the company rebranded to Novarex in November 2011.

BioLeaders Corporation is a healthcare company based in Yongin, South Korea, founded in 1999. The company focuses on developing innovative medicines, particularly in the field of oncology, with its flagship product being P53, an anti-cancer drug. BioLeaders is advancing several pipeline products, including BLS-H01, currently in phase 3 clinical trials for cervical cancer, and BLS-M07, which has completed phase 2b trials for the same condition. Additionally, the company is working on BLS-M22 for the treatment of Duchenne muscular dystrophy and BLC-H03, a vaccine adjuvant. Beyond pharmaceuticals, BioLeaders also offers health functional foods, raw materials, and functional cosmetic ingredients, positioning itself as a comprehensive provider in the healthcare sector.

Maniker F&G Co., Ltd. is a South Korean company that specializes in the production, processing, and sale of frozen, chilled, and retorted food products. Established in 1993 and headquartered in Yongin, the company offers a variety of chicken and beef items, including Ginseng chicken stew, Mung bean chicken stew, Premium Samgyetang, boneless chicken tenders, and popcorn chicken. Maniker F&G is committed to delivering safe and delicious food products through advanced meat processing technology. The company also exports its offerings to the United States, aiming to enhance customer health and convenience through continuous innovation and improvement.